教一个古老的药物一个新的技巧:针对性治疗阻力在生殖尿道癌症
Karina Aguilar1, Anuj K Sharma1, Tianyu Yang1
1Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, 1410 Laney Walker Blvd., 30912, USA.
概括
研究人员发现,Hymecromone可以增强Sorafenib.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 转移性细胞癌 (mRCC) 的治疗往往侧重于新的向疗法.
- 像Sorafenib这样的现有药物对mRCC具有适度的疗效.
- RCC细胞拥有禁用索拉芬尼的机制,限制了它的有效性.
研究的目的:
- 研究改善Sorafenib在mRCC中的疗效的方法.
- 为了确定RCC细胞失活Sorafenib的机制.
- 为了探索Hymecromone与Sorafenib结合的治疗潜力.
主要方法:
- 对乔丹等人研究的分析. (瘤发生 2020) 和王等人. (癌细胞 Int 2022).
- 研究氨酸合成酶-3 (HAS3) 在Sorafenib无活化中的作用.
- 在mRCC模型中评估Hymecromone对Sorafenib疗效的影响.
主要成果:
- 索拉菲尼布在RCC细胞中向氨酸合成酶-3 (HAS3).
- 菌素抑制了HAS3的表达和下游信号传递.
- 希米克罗蒙恢复并改善索拉费尼布对mRCC的疗效.
结论:
- 用Hymecromone针对HAS3可以克服mRCC中的索拉芬尼布耐药性.
- 重新利用像Hymecromone这样的现有药物提供了一种增强癌症治疗的策略.
- 提高具有良好的安全性概况的已知药物的疗效可以扩大晚期癌症的治疗选择.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
